A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors

SIMPLE SUMMARY: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have provided clinical benefits for a subset of patients with advanced breast cancer; however, treatment resistance generally emerges over time in patients with breast cancer, and the efficacy of existing CDK4/6 inhibitors in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Patnaik, Amita, Hamilton, Erika, Xing, Yan, Rasco, Drew W., Smith, Lon, Lee, Ya-Li, Fang, Steven, Wei, Jiao, Hui, Ai-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599640/
https://www.ncbi.nlm.nih.gov/pubmed/36291780
http://dx.doi.org/10.3390/cancers14204996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599640/
https://www.ncbi.nlm.nih.gov/pubmed/36291780
http://dx.doi.org/10.3390/cancers14204996

Ejemplares similares